Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tectonin beta-propeller repeat-containing protein 2 (TECPR2) is a large, multi-domain scaffold protein characterized by WD repeat domains at the N-terminus and TECPR repeats with a functional LC3-interacting region at the C-terminus[1][4][8][10]. TECPR2 is essential for autophagy, facilitating autophagosome formation, and mediating their targeting and fusion with lysosomes through interactions with ATG8 family members and tethering complexes such as BLOC1 and HOPS[1][4][8]. It coordinates secretory pathway trafficking by connecting the endoplasmic reticulum, Golgi apparatus, and vesicle export machinery, ensuring efficient maturation of autophagosomes and lysosomal degradation[1][2]. Loss-of-function mutations cause neurodegenerative syndromes, primarily spastic paraplegia type 49 (SPG49), intellectual disability, and hereditary sensory/autonomic neuropathies due to impaired autophagy and neuronal waste clearance[3][4][5][8][10]. TECPR2 is not classified as a receptor, enzyme, or canonical drug target, but is significant for understanding cellular waste management and neurodegenerative disease mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tectonin beta-propeller repeat-containing protein 2 (TECPR2).